253 related articles for article (PubMed ID: 18598222)
1. Caveolin-1: a marker for pancreatic cancer diagnosis.
Tanase CP
Expert Rev Mol Diagn; 2008 Jul; 8(4):395-404. PubMed ID: 18598222
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers of early pancreatic cancer.
Goggins M
J Clin Oncol; 2005 Jul; 23(20):4524-31. PubMed ID: 16002843
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
Dittert DD; Kielisch C; Alldinger I; Zietz C; Meyer W; Dobrowolski F; Saeger HD; Baretton GB
Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
[TBL] [Abstract][Full Text] [Related]
4. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
[TBL] [Abstract][Full Text] [Related]
5. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma.
Szafranska-Schwarzbach AE; Adai AT; Lee LS; Conwell DL; Andruss BF
Expert Rev Mol Diagn; 2011 Apr; 11(3):249-57. PubMed ID: 21463235
[TBL] [Abstract][Full Text] [Related]
6. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
Singh P; Srinivasan R; Wig JD
Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
[TBL] [Abstract][Full Text] [Related]
7. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
8. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.
La Rosa S; Klersy C; Uccella S; Dainese L; Albarello L; Sonzogni A; Doglioni C; Capella C; Solcia E
Hum Pathol; 2009 Jan; 40(1):30-40. PubMed ID: 18715612
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer: a plea for good and comprehensive morphological studies.
Algül H; Schmid RM
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):713-5. PubMed ID: 18617774
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma.
Giovinazzo F; Turri G; Zanini S; Butturini G; Scarpa A; Bassi C
Surg Oncol; 2012 Dec; 21(4):e171-82. PubMed ID: 22981281
[TBL] [Abstract][Full Text] [Related]
12. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy.
Nagata S; Jin YF; Yoshizato K; Tomoeda M; Song M; Iizuka N; Kitamura M; Takahashi H; Eguchi H; Ohigashi H; Ishikawa O; Tomita Y
Ann Surg Oncol; 2009 Sep; 16(9):2531-8. PubMed ID: 19499276
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.
Deng H; Shi J; Wilkerson M; Meschter S; Dupree W; Lin F
Am J Clin Pathol; 2008 Jan; 129(1):81-8. PubMed ID: 18089492
[TBL] [Abstract][Full Text] [Related]
14. Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease.
Bartosch-Härlid A; Andersson R
Pancreatology; 2010; 10(4):423-8. PubMed ID: 20720443
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Giaginis C; Katsamangou E; Tsourouflis G; Zizi-Serbetzoglou D; Kouraklis G; Theocharis S
Med Sci Monit; 2009 May; 15(5):BR148-56. PubMed ID: 19396032
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.
Winter JM; Yeo CJ; Brody JR
J Surg Oncol; 2013 Jan; 107(1):15-22. PubMed ID: 22729569
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology.
Mazur PK; Siveke JT
Gut; 2012 Oct; 61(10):1488-500. PubMed ID: 21873467
[TBL] [Abstract][Full Text] [Related]
18. Utility of immunohistochemistry in the pancreatobiliary tract.
Lin F; Chen ZE; Wang HL
Arch Pathol Lab Med; 2015 Jan; 139(1):24-38. PubMed ID: 25549142
[TBL] [Abstract][Full Text] [Related]
19. The need for effective pancreatic cancer detection and management: a biomarker-based strategy.
Crawley AS; O'Kennedy RJ
Expert Rev Mol Diagn; 2015; 15(10):1339-53. PubMed ID: 26394703
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of the beta4 integrin subunit in pancreatic adenocarcinoma.
Gleason B; Adley B; Rao MS; Diaz LK
J Histochem Cytochem; 2005 Jun; 53(6):799-801. PubMed ID: 15928331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
